Glaxosmithkline Biologicals Sa

Novartis Ag

Fabio Bagnoli

Guido Grandi

Vega Masignani

Luigi Fiaschi

Maria Scarselli

Nathalie Norais

Ravi Pratap Narayan Mishra

Massimiliano Biagini

Silvana Savino

Carine Goraj

Michele Pallaoro

Mikkel Nissum

Massimo Mariani

Fabiana Falugi

Claudio Donati

Paolo Ruggiero

Ravi Mishra

Alessandro Muzzi

Michéle Barrochi

The invention provides an immunogenic composition comprising staphylococcal antigens, containing protein antigens and conjugates of capsular polysaccharides, n particular Hla, ClfA, SpA and conjugates of capsular polysaccharides. Adjuvanted formulations are also provided. The invention may find use in the prevention and treatment of staphylococcal infections, in particularinfection and disease.

Immunogenic composition comprising staphylococcal antigens

Mutant protein A of(SpA) with decreased affinity for the Fc&#x3b3; portion of human IgG is provided.

Mutant staphylococcal antigens

An effectivevaccine may require several antigenic components, and so various combinations ofantigens are identified for use in immunisation. These polypeptides may optionally be used in combination withsaccharides.

[object Object]

Elimination of disulphide bond formation of cysteine-containingantigens enhances antigen stability. The invention provides variant forms of cysteine-containingantigen with a point mutation that replaces, deletes or modifies the cysteine residue.

An effectivevaccine may require several antigenic components, and so various combinations ofantigens are identified for use in immunization. These polypeptides may optionally be used in combination withsaccharides.

Hla polypeptides having various deletions, insertions, and/or mutations which are useful for immunization are provided herein. Also provided herein are Hla heptamers which are non-haemolytic. Additionally, an effectivevaccine may require several antigenic components, and so various combinations ofantigens, including Hla polypeptides having deletions, insertions, and/or mutations, are identified for use in immunization. These polypeptides may optionally be used in combination withsaccharides.

Growing community of inventors

Monteriggioni, Italy

Fabio Bagnoli